Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

• Main Authors: Douglas S. Walsh, Polrat Wilairatana, Douglas B. Tang, D. Gray Heppner, Thomas G. Brewer, Srivicha Krudsood, Udomsak Silachamroon, Weerapong Phumratanaprapin, Duangsuda Siriyanonda, Sornchai Looareesuwan
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/21353

Background. Tafenoquine is an 8-aminoquinoline developed as a more effective replacement for primaquine. In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administer...